Kura Oncology Funding & Investors
Kura Oncology, Inc. operates as a clinical stage biopharmaceutical company. The Company focuses on discovery and development of personalized therapeutics for the treatment of tumors and blood cancers. Kura Oncology offers development programs for cancers with high unmet need, including lung, colorectal, thyroid, blood, and pancreatic cancers.
kuraoncology.comTotal Amount Raised: $1,241,425,536
Kura Oncology Funding Rounds
Post Ipo Equity
$150,000,000
Post Ipo Equity Investors
Suvretta Capital ManagementEcoR1 CapitalDeerfield ManagementPost Ipo Equity
$100,000,000
Post Ipo Debt
$125,000,000
Post Ipo Debt Investors
Hercules CapitalPost Ipo Equity
$25,000,000
Post Ipo Equity Investors
Bristol-Myers SquibbPost Ipo Equity
$345,080,500
Post Ipo Equity
$143,900,000
Post Ipo Equity
$115,345,000
Post Ipo Equity
$77,050,000
Post Ipo Equity
$50,050,000
Post Ipo Equity
$50,000,000
Private Equity
$60,000,000
Private Equity Investors
EcoR1 CapitalArch Venture PartnersNextech InvestOsage University Partners (OUP)Fidelity InvestmentsTavistock GroupPFM Health SciencesIPO
Unknown
Funding info provided by Diffbot.